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ABSTRACT: Natural compounds are an important class of potent drug molecules including some retro-
spectively found to act as stabilizers of protein-protein interactions (PPIs). However, the design of syn-
thetic PPI stabilizers remains a poorly investigated approach. To this date, there are no general procedures 
available to evaluate the induced cooperativity of the interacting proteins due to the stabilizer molecule. 
The 14-3-3 scaffold proteins provide an excellent platform to explore PPI stabilization because these pro-
teins mediate several hundred PPIs, and a class of natural compounds – the fusicoccanes – are known to 
stabilize a number of 14-3-3 protein interactions. 14-3-3 has been reported to negatively regulate the p65 
subunit of the NF-κB transcription factor, qualifying this protein complex as a potential target for drug 
discovery in order to control cell proliferation. Here, we report the high-resolution crystal structures of 
two 14-3-3 binding motifs of p65 in complex with 14-3-3. A semi-synthetic natural product derivative – 
DP-005 – binds to an interface pocket of the p65/14-3-3 complex and concomitantly stabilizes it. Coop-
erativity analyses of this interaction, and other disease relevant 14-3-3-PPIs, demonstrated selectivity of 
DP-005 for the p65/14-3-3 complex. The adaptation of a cooperative binding model provided furthermore 
a general approach to characterize stabilization and to assay for selectivity of PPI stabilizers. 
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INTRODUCTION 
The need to develop new strategies that address the challenges of today’s most important diseases, has 
motivated efforts to modulate protein-protein interactions (PPIs), which has become an increasingly at-
tractive approach for drug discovery.1–4 Promising progress has been made on both inhibition and stabili-
zation of PPIs, but especially the ab initio design of PPI stabilizers is still the exception.3 Nature itself 
provides the most potent and selective stabilizers of PPIs, validating the concept of stabilization as a 
valuable strategy for targeting PPIs.5,6 The mode of action of known PPI stabilizers was mostly discovered 
retrospectively, as for example with rapamycin (Rapamune®, Pfizer), cyclosporin (Sandimmun®, Novar-
tis Pharmaceuticals) or FK506 (Prograf®, Astellas Pharma). 5–7 
In order to achieve PPI stabilization, the binding equilibrium of two target proteins needs to be shifted to 
the complexed state by binding of a third interaction partner, preferably a drug-like small molecule. This 
underlying binding improvement can be described via cooperative binding models whereby the increased 
binding affinity of the interaction partners, due to the formation of a ternary complex, is quantified via the 
cooperativity factor .8–11 Adapting the cooperativity model to PPI drug discovery projects has been an 
underexplored opportunity which has however started to gain more attention since PROTACs (proteoly-
sis-targeting chimeras) were shown to induce cooperative binding of their protein binding partners.12 In 
this work, using the interactions of 14-3-3 proteins as an example, we show that cooperativity analysis 
not only provides a description of binding properties but can also be used as a direct entry to establishing 
selectivity of compounds stabilizing PPIs. The 14-3-3 family of proteins pertain to the adaptor proteins 
which represent one of the most important protein classes in the PPI field, since they mediate interactions 
between proteins and  
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Figure 1: Interaction of p65 and 14-3-3. (A) Schematic representation of the interaction of 14-3-3, p65 and IκBα in context of the NF-κB 
pathway. Briefly, upon activation of the pathway (for example by TNF) a signal cascade (represented by a thick dashed arrow) leads to the 
phosphorylation and degradation of IκBα and the nuclear translocation of NF-κB (here represented by p50/p65). Binding of IκBα and 14-3-
3 to p65 are necessary for nuclear export or cytosolic retention (narrow dashed arrow). (B) Domain representation of the p65 protein, with 
the Rel Homology Region (RHR), the two transactivator domains (TA1, TA2) and amino acid sequences of the three conserved potential 
14-3-3 binding sites. (C) Cartoon representation of the crystal structure of the complex of IκBα with RHR domain of p65, with Van der 
Waals’ transparent surface. p65 (red to yellow) with IκBα (blue) (PDB ID: 1IKN; p50 hidden for clarity; S45 and S281 are highlighted for 
clarity). 
 
thereby regulate the function of their partner proteins.13,14 The 14-3-3 proteins recognize and bind phos-
phoserine/threonine motifs of hundreds of protein partners in eukaryotic cells, subsequently altering the 
catalytic activity, subcellular localization, or interactional preference of their partners.15,16 14-3-3 is func-
tionally present as a w-shaped dimer featuring two highly conserved, amphipathic grooves, where the 
phosphorylated residues are bound.17 A key element for the promising development of 14-3-3 proteins as 
potential drug targets is the availability of multiple members of a class of natural products - the fusicoc-
canes (FCs) – that have been demonstrated to stabilize the binding of 14-3-3 proteins to a number of 
partner proteins.18–22 Protein crystallography studies have shown for example how such FCs stabilize 14-
3-3 binding to protein targets like p53,18 c-Raf,19 ER,20 Gab221 and CFTR.22 These natural compounds 
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bind to protein pockets delineated by the interface of the complex of 14-3-3 and its partner protein. In this 
way, FCs establish contacts to both protein partners simultaneously, acting as a molecular glue.5,23 
Among the 14-3-3 partners are at least two proteins that crucially participate in the NF-κB pathway.24–26 
The NF-κB signaling pathway has raised considerable attention as a therapeutic target, because of its 
intimate involvement in cell proliferation, apoptosis, immunity, and inflammation via the expression of 
several hundred genes.27–29 NF-κB proteins are dimeric transcription factors which are sequestered out of 
the nucleus into the cytosol by inhibitor proteins. Upon activation of the NF-κB pathway, for example by 
TNF, NF-κB translocates to the nucleus and activates transcription (Figure 1A). Inhibition of this tran-
scriptional activity has been the goal of numerous drug discovery campaigns, however only a limited 
number of inhibitors of the NF-κB pathway are currently marketed drugs, none of which directly target 
NF-κB.30–32 The NF-κB subunit p65 and its inhibitor IB bind to 14-3-3, which favors localization of 
p65 in the cytosol.24 Only limited information about the p65/14-3-3 interaction is available, even though 
downregulation of 14-3-3 leads to increased transcriptional activity of p65 in both, a breast cancer model25 
and studies on Ischemia-Reperfusion.26 Stabilization of the p65/14-3-3 complex might therefore inhibit 
the transcriptional activity of p65, opening a new and unique opportunity for p65-specific NF-κB inhibi-
tion.  
In this study we provide the structural and biophysical data and analysis to substantiate the biological 
interaction studies of the p65/14-3-3 interaction. We tested several natural and semi-synthetic FCs as po-
tential small molecule stabilizers of this intriguing PPI, revealing the semi-synthetic DP-005 as the most 
active compound. A detailed analysis of the cooperative binding of the FCs, and DP-005 in particular, to 
the p65/14-3-3 interaction and multiple other disease relevant 14-3-3 PPIs was performed. DP-005 was 
at least 10-fold more active in stabilizing the p65/14-3-3 interaction than any other tested combination of 
FC and 14-3-3 PPI. The analysis clearly demonstrates that the cooperativity factor  can be used to quan-
tify these stabilizing effects and is an underlying factor in achieving selectivity of stabilizer molecules on 
PPIs. 
 
RESULTS AND DISCUSSION 
Interaction of p65 and 14-3-3. In p65, the sequence surrounding three serines – S45, S281, S340 – 
matches to 14-3-3 consensus binding motifs (Figure 1B).17 Mutations of these serine residues to alanines 
was previously shown to reduce p65 binding to 14-3-3 in cells and to increase the p65 concentration in 
the nucleus.24 The S45 and S281 sites are phosphorylated in response to TNF treatment33 and both are 
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highly conserved within mammals (Figure S1). No TNF dependent phosphorylation has been reported 
for the S340 site,33 which is also less conserved (Figure S1). The pS45 and pS281 sites are located in 
unstructured loop regions of p65 and the folding of p65 brings these two residues into proximity with 
each other, implying the  possibility for a bivalent interaction with the 14-3-3 dimer (Figure 1C).22,34,35 
 
 
Figure 2: The binary complex of p65 peptides and 14-3-3. (A,B) The binding affinities of the indicated bivalent p65 peptides (100nM) to all 
human 14-3-3 isoforms were measured via fluorescence anisotropy (r in mAU) assays. (C) KD values in μM of the p65_biE and p65_biR to 
the different 14-3-3 isoforms. (D) High resolution X-ray crystal structures of p65_45R (PDB ID: 6QHL). The peptide shows a C-terminal 
curved conformation leaving the typical FC binding pocket more or less accessible (blue circle). (E) High resolution X-ray crystal structures 
of p65_281 (PDB ID: 6QHM) in complex with 14-3-3σΔC. The proteins are either displayed as white surface or cartoon (close up); water 
molecules are shown as red spheres. The 2mFo-Fc electron density map is displayed with =1. Polar contacts between protein and peptides 
are indicated as yellow dashed lines. Sequence of the p65_45R peptide: EGRSAGpSIPGRRS; sequence of the p65_281 peptide: 
PSDRELpSEPMEFQ (residues visible in the electron density are bold). 
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In order to represent these interaction motifs, peptides of 13 amino acids were synthesized for the pS45 
and pS281 site (Table 1). Noteworthy, for the pS45 site two different sequences are available: whereas the 
canonical sequence features a glutamate at position 49, a second sequence identified an arginine instead.36 
Since no biological or phenotypic relevance of these variants are reported,36 both sequences were tested 
for binding, hereafter termed p65_45E and p65_45R after the phosphorylation site S45 and the variant of 
amino acid 49. Each peptide is centered around the phosphorylated serine, flanked by six amino acids of 
the wildtype sequence on each side. To mimic the expected bivalent binding mode of the p65/14-3-3 
complex double phosphorylated peptides were synthesized, connecting the two binding sites with a flex-
ible linker (Table 1). 
Elaboration of 14-3-3 binding motifs of p65. In a first step, the binding affinities of the two conserved 
14-3-3 binding motifs of p65 were measured. To this end, the p65-peptides were labeled with a fluoro-
phore and fluorescence anisotropy assays (FA) were performed. Both single site binding epitopes showed 
an increase in FA upon addition of 14-3-3 proteins, although not with full binding saturation (Figure S2). 
This confirms weak binding of both sites to all human 14-3-3 isoforms. The bivalent peptides featured a 
significantly stronger binding affinity to all 14-3-3 isoforms, with the p65_biR binding roughly 2-fold 
stronger than the p65_biE peptide (Figure 2A-C). The strongest binding was observed with 14-3-3 
(𝐾𝐷𝐸49=21.6±1.8 M; 𝐾𝐷𝑅49 = 10.0±1.9 M), directly followed by 14-3-3 (𝐾𝐷𝐸49=36.7±3.8 M; 𝐾𝐷𝑅49=17.5±3.3 M), The dissociation constants of 14-3-3, , , and  with p65_biR ranged from 38 to 
127 M (Figure 2C), while 14-3-3 showed the weakest binding (Figure 2C), not atypical for 14-3-
3.22,37,38 The peptide-protein binding data thus confirm a physical interaction between p65 and 14-3-3 and 
argue in favor of a bivalent binding event. 
The binding between p65 and 14-3-3 was further elucidated with structural data; the single phosphorylated 
peptides were co-crystallized with 14-3-3C (last 17 unstructured residues on the C-terminus are trun-
cated) resulting in high resolution structures of 1.2 and 1.25 Å for the p65_45R, and p65_281 complexes, 
respectively (Table S1). The phosphorylated S45 makes polar contacts with R56, R129 and Y130; the 
general phospho-accepting pocket of 14-3-3 (Figure 2D; PDB-ID: 6QHL). Upstream of pS45 only A43 
and G44 are visible in the electron density map, whereby the backbone of G44 makes polar contacts with 
N226 of the 14-3-3 protein. At the +1 position of pS45 the isoleucine points into a hydrophobic pocket of 
the 14-3-3 binding groove making hydrophobic contacts with L174, I219, and L222. The presence of a 
proline residue at the +2 position results in a curved conformation in the binding groove, potentially cre-
ating a ligandable interface pocket (Figure 2D). In comparable crystal structures of 14-3-3 with other 
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interaction partners, a similar pocket accommodates FCs and their derivatives.18,19,21 The sidechain of R49 
makes two polar contacts with N50 of 14-3-3 as well as with several water molecules. The C-terminus of 
the p65_45R peptide makes additional polar contacts with E14 of 14-3-3. The direct comparison of the 
two variants of the p65_45 peptide only shows small differences in binding affinity and structural infor-
mation could only be obtained for the p65_45R peptide, hence this variant was selected for the next ex-
periments. 
Table 1: Overview of synthetic peptides representing the proposed 14-3-3 binding motifs of p65. 
Name Phospho-
site 
Peptide Sequence 
p65_45E pS45 EGRSAGpS45IPGE49RS 
p65_45R pS45 EGRSAGpS45IPGR49RS 
p65_281 pS281 PSDRELpS281EPMEFQ 
p65_biE pS45pS281 EGRSAGpS45IPGE49RSGSGGGSG 
PSDRELpS281EPMEFQ 
p65_biR pS45pS281 EGRSAGpS45IPGR49RSGSGGGSG 
PSDRELpS281EPMEFQ 
 
The electron density of the p65_281 peptide in complex with 14-3-3 revealed only the backbone of two 
additional amino acids besides that of the phosphorylated serine (Figure 2E; PDB ID: 6QHM). Additional 
electron density on the N-terminus of the peptide could not be fully interpreted, indicating multiple con-
formations of these amino acids. The phosphoserine is trapped in the binding groove via polar contacts 
with R59, R129 and Y130 of 14-3-3C. Additionally, contacts could also be observed with the backbone 
nitrogen of E282, at the +1 position of p65_281, and N175 of 14-3-3 and the carbonyl of L280 of the 
peptide and N226 of the protein. 
Fusicoccanes stabilize the p65/14-3-3 interaction. The structures of p65_45R and p65_281 provide the 
structural basis to investigate possible molecular strategies to stabilize these binary complexes. Since the 
14-3-3 binding groove is highly conserved, the p65-peptide/14-3-3C interface displays the key molec-
ular details of the primary p65/14-3-3 interface.17 The p65_45R peptide is bending in a way that the typical 
FC binding pocket remains accessible and the conformation of the p65_281 is unknown (Figure 2D,E). 
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This leaves the possibility that both complexes may be stabilized by FCs or synthetic derivatives thereof. 
The FCs share a diterpene core with a 5(A)-8(B)-5(C) ring structure (Figure 3A);39 modifications that 
include additional sugar moieties, hydroxylation or acetylation have introduced considerable chemical 
diversity into this compound family (Figure 3B).40 
The effect of FCs on the p65/14-3-3 complex was investigated with a small collection of eight natural 
FCs and their semi-synthetic derivatives (Figure 3B). The tested FCs have a FC-A like structure with a 
hydroxylation on position 8, a methoxy group at position 16 and a sugar moiety at position 9. The main 
variations within the collection used here are on the sugar moiety, position 12, and/or 19. FC-A contains 
an additional acetyl on the 19 position, while the natural product FC-J only has an isopropyl on the C-
ring. A recent study showed that replacing the acetyl with an acetamide (FC-NAc) improves the affinity 
to 14-3-3 with various partners.23 The 12-position is hydroxylated in the natural compounds, but this 
position is not hydroxylated in the semi-synthetic derivatives DP-005 and ISIR-00521,41 and a bulky group 
was introduced for FC-THF.42 For FC-A-aglycon (FC-A-ag)42 and FC-J-aglycon (FC-J-ag)42 the sugar 
moiety was removed. Initially, a single-dose of compound and protein concentration was tested using FA. 
The single phosphorylated peptides were used so that a potential stabilizing effect could be correlated to 
a specific binding motif. 14-3-3 was used because of the highest binding affinity of all peptides to this 
isoform. 
The FA results showed that several FCs have a stabilizing effect on the p65_45E/14-3-3 and p65_45R/14-
3-3 interaction (Figure 3C; Figure S3), while they do not stabilize the p65_281/14-3-3 complex (Figure 
S3). The fusicoccanes FC-A, FC-J and FC-NAc elicited about two-fold higher anisotropy signal of the 
p65_45R/14-3-3 PPI compared to the DMSO control. Interestingly, semi-synthetic analogues DP-005 
and ISIR-005 induced a stronger increase in the anisotropy signal (about three-fold). Bulky extensions at 
the C-ring (FC-THF) and the absence of the sugar moiety (FC-A-ag and FC-J-ag) abrogated the ability to 
stabilize the p65_45R/14-3-3 complex. A hydroxyl group at the 12-position or its ring-extension thus 
cause a loss in activity. The negligible activity of the aglycons is in line with previous work on these 
synthetic variants, generally showing lower activity.42 
The stabilizing effects of FC-A and DP-005 were further investigated via 14-3-3 protein titrations to the 
p65_45R peptide at a set concentration of DP-005, FC-A, or the DMSO control (Figure 3D). The protein 
titrations confirmed the stronger stabilizing effect of DP-005 as compared to FC-A, with a clear left shift 
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of the binding curve, affording apparent KD values of 2.8±0.1 M and 38.9±2.4 M respectively. Con-
straining the fitting for the DMSO control, using the upper plateau of the DP-005 and FC-A binding 
curves, results in an apparent KD of about 350 μM for the p65_45R/14-3-3γ complex.  
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Figure 3: Stabilizing effect of fusicoccanes on the p65_45/14-3-3 interaction. (A) The diterpene skeleton of the fusicoccane family. Encircled 
are the positions which are of interest in this study. (B) A collection of eight FCs used to screen for a stabilizing effect on the p65/14-3-3 
complex. (C) FA-based screening results of the FC-collection shown in B on the p65_45R-14-3-3 complex. The anisotropy (r in mAU) 
measurements were carried out with 100 M compound, 50 M 14-3-3 and 100 nM of p65_45R. Error bars represent standard deviations 
of two independent measurements performed in technical triplicates. (D) Titration of 14-3-3 in the presence of 100 M compound or DMSO 
control (ctrl) and 100 nM p65_45R measured with FA. Error bars represent standard deviations of three independent singlet measurements. 
(E) Titration of compound or DMSO control (ctrl) in presence of 50 M 14-3-3 and 100 nM p65_45R measured with FA. Error bars represent 
standard deviations of three independent singlet measurements. 
 
Hence, the improvement in peptide stabilization acquaints to approximately 10-fold (FC-A) and 100-fold 
(DP-005) compared with the DMSO control. Finally, the effective concentrations of FC-A and DP-005 
were determined by titrating the compounds to a fixed protein and peptide concentration of 50 μM and 
100 nM respectively. This gave an EC50 of 9.4±2.0 M for the semi-synthetic compound DP-005, while 
the natural compound FC-A showed a weaker activity with an EC50 of 17.1±1.8 M (Figure 3E). 
Crystallography and NMR provides structural confirmation of the FC binding to p65/14-3-3. To 
corroborate the stabilization and SAR obtained using FA, we sought a structural analysis of the ternary 
complex of DP-005 with p65_45R/14-3-3. For this purpose, DP-005 was soaked into crystals of the pre-
formed p65_45R/14-3-3C complexes, revealing extra electron density for the p65_45R/14-3-3C 
crystals. This electron density allowed for the complete refinement of DP-005 (Figure 4A, Table S1, PDB 
ID: 6NV2). The crystal structure provided detailed information about the orientation of the diterpenoid 
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core and the sugar moiety. Of note, the orientation of the peptide changed significantly upon binding of 
DP-005 (Figure 4B). In particular, amino acid P47 changed from a trans- to a cis-conformation and the 
residues from G48 to S51 moved away from the ligand. The most prominent interactions between DP-
005 and the protein complex are the hydrophobic contacts with I46 and P47 of p65_45R as well as with 
L218, I219 and L222 of 14-3-3C (Figure 4C). Noteworthy is the contact of the methoxy group of DP-
005 with the -amino group of K122 of the protein, while the sugar moiety was surrounded by the water 
shell of 14-3-3C (Figure 4D). The fact that FC-aglycons showed only a negligible activity, might be 
due to the importance of this sugar-water shell interaction. 
An overlay of FC-A with the conformation of DP-005 points out the impact of the singular hydroxyl group 
at the 12-position of FC-A, not present in DP-005, on the binding to the protein complex (Figure 4E). The 
hydroxyl group would have an orientation that would induce a steric and polar clash with hydrophobic 
elements of the peptide. This indicates that the peptide would potentially require further rearrangements 
in order to accommodate the binding of FC-A, potentially explaining why the ternary structure of FC-
A/p65_45R/14-3-3C could not be determined with X-ray crystallography. 
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Figure 4: Structural analysis of the ternary DP-005/p65/14-3-3 and FC-A/p65/14-3-3 complexes. (A) Crystal structure of DP-005 (green 
sticks), p65_45 (red sticks) and 14-3-3C (white surface) (PDB ID: 6NV2). (B) Binding of DP-005 induces a re-orientation of the p65_45 
peptide (original conformation of binary complex: black sticks; ternary complex with DP-005: red sticks). (C) Hydrophobic contacts are 
indicated with spheres. (D) Polar contacts of DP-005 displayed as yellow dashed lines with the polar contact of the methoxy group of DP-
005 and K122 highlighted with black dashed lines. (E) Overlay of FC-A (blue sticks) and DP-005 (green sticks). An arrow indicates the 
hydroxyl group at position 12 which causes the difference in affinity between both compounds. Hydrophobic residues of the peptide/protein 
complex are shown as spheres. (F) The resonance corresponding to the W230 N-H bond of 14-3-3 was monitored to detect the stabiliza-
tion of this PPI. This resonance is circled in black on the 1H-15N TROSY-HSQC spectrum of 15N13C2H-labeled 14-3-3 (shown on the right) 
and the corresponding residue W230 is represented as sticks, colored in blue and circled in black on the crystal structure (shown on the left, 
represented as white surface). This residue is close to the peptide-binding site and distant from the FC-A binding site. (G-J) The enlarged 
spectral region of the 1H-15N TROSY-HSQC containing the resonance corresponding to the W230 N-H bond of 14-3-3 (125 µM) is 
shown in the presence of: DMSO 4% (v/v), present in all samples (G) , FC-A 125 µM (H), p65_45R peptide 625 µM (I) and p65_45R peptide 
625 µM and FC-A 125 µM (J).  
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As an alternative to obtaining structural information on the binding of FC-A to the binary p65/14-3-3 
complex, NMR measurements were performed, based on the assignments of 14-3-3 signals.43 Chemical 
shift perturbations in the resonances corresponding to specific residues along 14-3-3 confirmed that FC-
A binds in its previously reported binding pocket, in the presence and in the absence of the p65_45 peptide 
(Figure S4). To specifically monitor the binding event of p65_45R to 14-3-3, we focused on the 1H-15N 
TROSY-HSQC signature of residue W230 side-chain of 15N13C2H labeled 14-3-3. This residue is spe-
cifically affected by the p65_45R peptide binding, but not by the FC-A binding, as can be expected from 
its remote position from the FC-A binding pocket (Figure 4F). Its side-chain N-H resonance has a clear 
signature because it is isolated in the spectrum (Figure 4F) and is unambiguously assigned (Figure S5). 
Monitoring the resonance intensity of N-H W230 revealed that the intensity of this resonance is, as 
expected, not affected by the presence of FC-A alone (Figure 4G,H). Addition of the p65_45R peptide 
alone results in resonance broadening due to the binding, and an intensity drop to 80% as compared to the 
reference spectrum (Figure 4I). Addition of FC-A together with the p65_45 peptide resulted in the most 
pronounced decrease of the intensity of the N-H W230 resonance, down to 20% (Figure 4J). The data 
thus orthogonally confirm the stabilization of the p65_45R/14-3-3 complex by FC-A. 
Preferential stabilization of the p65/14-3-3 complex by DP-005. The stabilization of p65/14-3-3 by 
DP-005 was significantly stronger than the effect of FC-A (vide supra), raising the question about DP-
005 impact on other FC responsive 14-3-3 PPIs. Crucial differences between FC-A and DP-005 are the 
additional polar decorations of FC-A at positions 12 and 19 (Figure 3 A,B). Hence, we hypothesized based 
on the crystal structure of the ternary complex that the hydrophobic contacts of the Ile and Pro at the +1 
and +2 positions of the p65_45R peptide match the complementary driving force of the DP-005 based 
stabilization. Within the FC responsive 14-3-3 PPIs, diverse amino acid sequences C-terminal from the 
phosphorylation site, can be found.18–22 We investigated the effects of FC-A and DP-005 on a small set of 
three different clinically relevant 14-3-3 interaction partners (CFTR,44,45 c-Raf35,46 and p5347,48) which 
differ in size and hydrophobicity of the +1 amino acid (Figure 5A).  
CFTR binds to 14-3-3 via multiple phosphorylation sites, for which the combination of two, pS753 and 
pS768 (CFTR_bi), was suggested to give a suitable representation of the biological situation.22 Both bind-
ing sites host a valine at the +1 and an isoleucine or leucine at the +2 position and they bind in an elongated 
manner within the 14-3-3 binding groove (Figure 5A, Figure S6A,B). Upon binding of FC-A only the 
pS753 site is flexible enough to rearrange allowing the formation of a ternary complex (Figure 5B, Figure 
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S6C). FA assays with the single phosphorylated peptides, representing the two binding sites, confirm that 
only the pS753 site is responsive to FC-A or DP-005 (Figure S6A,B).  
The example of CFTR is particularly interesting since the binding behavior of the CFTR peptides show 
similarities with the p65 peptides: for both interactions a bivalent binding mode is suggested and only one 
of the two binding sites is responsive to FCs. Therefore, the bivalent p65_biR and CFTR_bi peptides were 
used to measure the effects of FC-A and DP-005 on complex formation with 14-3-3γ. While FC-A and 
DP-005 have the same stabilizing effect on the bivalent CFTR_bi/14-3-3γ PPI, DP-005 has a 10x stronger 
stabilizing effect than FC-A on the p65_biR/14-3-3γ complex (Figure 5 C-E). The relative shift in apparent 
KD induced by the FCs are the same for the monovalent p65_45R and the bivalent p65_biR (Figure 3D, 
Figure 5D,E), showing that the increased binding affinity of the bivalent peptide does not change the 
stabilizing effects of FCs on the binding site pS45 of p65. Also, DP-005 is more active on the p65/14-3-
3γ than the CFTR/14-3-3γ complex, although the CFTR_753 peptide offers a similar hydrophobic envi-
ronment as the p65_45R peptide. Based on the crystal structures, it can be hypothesized that the +2 position 
is crucial for this difference. Due to the alternating orientations of the amino acid side chains of unstruc-
tured motifs the isoleucine at the +2 position of the CFTR_753 is pointing towards the phosphorylated 
residue (Figure S6). In this orientation the Ile is not able to establish favorable hydrophobic contacts with 
DP-005, unlike the proline at the +2 position of the p65_45 peptide (Fig. 4C). 
For c-Raf two 14-3-3 binding sites are reported, pS233 and pS259, which both host a more polar threonine 
at the +1 and a proline at the +2 positions (Figure 5A).19 This interaction is not stabilized by FC-A11, 
therefore it was interesting to analyze the stabilization achievable with DP-005 on the c-Raf_259/14-3-3 
complex. In the presence of DP-005 the c-Raf_259 peptide binds 2x stronger to 14-3-3γ, while the lack 
of stabilization for FC-A could be reproduced (Figure 5C-E). This shows that a small polar amino acid at 
the +1 position reduces the stabilizing effect of DP-005, confirming that mostly hydrophobic contacts 
between this FC derivative, the peptide and 14-3-3 are necessary to establish the cooperative binding. 
p53 binds to 14-3-3 via its C-terminal domain and one of multiple possible phosphorylated binding sites. 
The pT387 site, was co-crystallized with 14-3-3,47–49 the binding sequence is bound in a bent conformation 
to the 14-3-3 binding groove and it hosts a large, polar glutamic acid at the +1 position (Figure 5A,B). 
The bent motif should allow FCs to bind, but crystal structures of the ternary FC-A/p53/14-3-3σΔC com-
plex showed that the electron density for the peptide is not resolved in the presence of FC-A.18 Still, FC-
A shows a stabilization of the p53/14-3-3 interaction by reducing the apparent KD by a factor of 2, whereas 
DP-005 has no significant effect on the p53/14-3-3 complex (Figure 5C-E). DP-005 thus has a specific 
and very strong stabilization effect on the p65 sequence exclusively. 
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Cooperativity Factor as a Measure of Concentration Independent Stabilization. The relative effect 
of a set FC concentration on the examined 14-3-3 PPIs revealed major differences in stabilization potency. 
These measurements were performed at a single, fairly high concentration of FCs and give no information 
about the effective range of FC concentrations, the concentrations needed to reach saturation of the system 
or the low threshold concentration necessary to achieve stabilization. Cooperativity analysis was done in 
order to gain a deeper understanding of relevant concentrations and to quantify the preferential stabiliza-
tion of p65 by DP-005, over other targets via the concentration independent cooperativity factor  (Figure 
S7, Table S2). The -factor describes the enhancement of binding affinity of a ternary complex formation 
compared to a binary complex.9,11,12 To calculate this factor, 14-3-3 titrations were performed in the 
presence of a variety of constant concentrations of DP-005 or FC-A stabilizer on the p65, CFTR, c-Raf, 
and p53/14-3-3 interactions (Figure 6A,B, Figure S8,S9). The highest FC concentration used was 250 μM 
which was reduced stepwise in a 1:2 dilution series. At increasing concentrations of compound, the protein 
has an increasing partial occupancy of bound stabilizer during the titrations. Due to cooperative binding 
this leads to more peptide binding at lower protein concentrations, hence a left shift of the binding curves 
resulting in a 2D stabilizing-profile.11 
For FC-A the apparent KD’s of the p65_biR and CFTR_bi in complex with 14-3-3γ shift an order of mag-
nitude from about 10 μM to 1 μM for both peptides (Figure 6A). Increasing concentrations of FC-A also 
induce a shift in the upper plateau, most likely due to a tighter binding peptide. Unlike FC-A, DP-005 
induces about a 100-fold decrease of apparent KD-values for the p65_biR/14-3-3γ complex, while the 
curves for the DP-005/CFTR_bi/14-3-3γ complexes are comparable to the curves for FC-A with a shift 
of only one order of magnitude (Figure 6B). DP-005 also causes an increase of anisotropy values for the 
upper plateau. These data were fitted using the Hill equation and the resulting apparent KD’s in presence 
of the FCs (KDapp) were divided by the KD of the binary complex (KDI). It is expected that at a certain 
stabilizer concentration the system is saturated, resulting in no further reduction of apparent KD-values 
with increasing concentrations of stabilizer. This saturated system can be used to extrapolate the cooper-
ativity factor  (Figure 6C, Table S2). This value represents the maximum reduction of KD induced via 
the stabilizer and can be derived from the ratio of the dissociation constant of the binary complex and the 
apparent KD of the complex saturated with stabilizer (more information see SI). By plotting the KDI/KDapp 
ratio versus the FC concentration not only the -factor, but also a threshold concentration can be extracted 
(Figure 6D,E). This concentration is the minimal required FC concentration needed to induce cooperative 
formation of the ternary complex. The threshold concentration of FC-A was 10 μM for both the p65_biR 
and CFTR_bi (Figure 6D,E). The FC-A/p65/14-3-3γ complex reached saturation with 30 μM FC-A, as 
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higher concentrations do not change the ratio of KDI/KDapp anymore (Figure 6D). At the point of saturation, 
the KDI/KDapp gives an -value of 5 for the FC-A/p65/14-3-3γ, while for the FC-A/ CFTR_bi/14-3-3γ an 
-value of 8 is reached. An -value of 10 was determined for the DP-005/CFTR_bi/14-3-3γ complex, 
also with the threshold concentration of 10 μM to induce cooperative binding. In contrast, only 1 μM of 
DP-005 is needed to induce cooperativity of the DP-005/p65/14-3-3γ complex with an -value of 120; at 
least 10x higher than any other measured -value. DP-005 revealed only a small enhancement of apparent 
KD values for c-Raf and p53, even at the highest concentrations. The higher concentrations of FC-A led 
to a further decrease of KDapp and resulted in an -value of 3 for the FC-A/p53/14-3-3γ complex. In con-
trast, the destabilizing effect of FC-A on the c-Raf/14-3-3γ complex becomes more obvious at higher 
concentrations, while the higher concentrations of DP-005 did not further decrease the KDapp. An -value 
of about 1.5 was determined for the DP-005/c-Raf/14-3-3γ and the DP-005/p53/14-3-3γ complex. 
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Figure 5: Comparison of FC induced stabilization on 14-3-3 PPIs. (A) Overview of 14-3-3 binding epitopes. (B) Overlay of the crystal 
structures of the binding epitopes shown in A (cartoon representation, phosphorylated residue and +1 amino acid shown as sticks). FC-A is 
shown as transparent spheres, 14-3-3 as white van der Waals surface. (C) Binding affinities of indicated peptides were measured for 14-3-
3γ in the presence of DMSO as control (ctrl), 100 μM FC-A or 100 μM DP-005 with FA (r in mAU). For peptide sequences see Table 1 and 
S3). (D) KDapp values in μM for the indicated peptides for the DMSO control (ctrl) or with FC-A or DP-005. (E) Increase in affinity of the 
binding partners due to FC-A or DP-005 shown as the ratio of the dissociation constant of the DMSO control (KDI) divided by the dissociation 
constant in the presence of either FC-A (KDFC-A) or DP-005 (KDDP-005). The numbers indicate the factor with which the binding affinity is 
enhanced due to the FCs compared to the control. 
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Figure 6: Cooperativity Analysis of FC-A and DP-005 on 14-3-3 PPIs. (A) 2D FA-results of FC-A with p65_biR/14-3-3γ and CFTR_bi 
(n=1). FC-A concentrations ranging from 0-250 μM, the vertical grey line indicates the peptide concentration. Anisotropy (r) given in mAU. 
(B) 2D FA-results of DP-005 with p65_biR/14-3-3γ or CFTR_bi (n=1). DP-005 concentrations ranging from 0-250 μM, the vertical grey line 
indicates the peptide concentration. (C) Scheme of 2D Titration in FA. 14-3-3 was titrated against 100nM of peptide (P) varying fixed 
concentrations of stabilizer (S). The data analysis was based on a one-to-one binding model. For cooperativity analysis the ratio of KD of the 
binary (KDI) and ternary (KDapp) complex was used to derive the cooperativity factor  (for derivation of the equations and additional infor-
mation see SI). (D) KDI/KDapp ratio plotted against FC-A concentration for 2D titrations shown in A and Figure S8. The arrow is indicating 
the minimal active concentration of the stabilizer, while the curve reaches saturation at the -value. (E) KDI/KDapp ratio plotted against DP-
005 concentration for 2D titrations shown in B and Figure S9. Analysis is in accordance with D. (F) The cooperativity value  for the ternary 
complexes with 14-3-3γ and either FC-A or DP-005 was plotted against the different target peptides. DP-005 has a 10-fold stronger effect 
on the p65/14-3-3γ interaction than any other measured interaction. 
 
CONCLUSIONS 
The NF-κB transcriptional pathway plays an essential role in immune response and its deregulation leads 
to cancer promotion. Targeting this pathway is an unsolved challenge in drug development. A recent re-
view concluded that the intense cross-talk of the numerous signaling pathways acting on the NF-κB tran-
scription factors as well as the only partly understood interplay of the different NF-κB subunits are re-
sponsible for the reoccurring failures during clinical trials despite the promising biological studies.32 A 
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more focused approach to target specific subunits of NF-κB was suggested. PPI stabilization of p65, a 
subunit of NF-κB, and 14-3-3 may provide such an opportunity to target NF-κB activity in a subunit 
specific manner. The interaction of p65 with 14-3-3 is associated with reduced tumor growth in mouse 
models and recovery after Ischemia-Reperfusion,24–26 validating this interaction for PPI stabilization stud-
ies. Yet, a better fundamental understanding of this interaction in the context of the NF-κB pathway is 
needed, particularly with regard to translational drug discovery. A stabilizer for the p65/14-3-3 interaction 
would serve as a tool compound to decipher this pathway and provides a chemical entry point for drug 
design. The results presented in this manuscript bring the p65/14-3-3 complex forward as an excellent 
candidate for PPI stabilization, specifically due to the orientation of the p65_45R peptide within the 14-3-
3 binding groove, creating a well-defined interface pocket that could be stabilized with FC-based natural 
products.  
Natural compounds provide for unique tools to probe and interrogate unique regions of chemical space,50 
which can be extended and brought to higher levels of control and specificity through their chemical 
modifications.23 A number of 14-3-3-based PPIs are stabilized by FCs with correlated positive effects on 
the underlying biological systems, such as tumor growth reduction by Cotylenin A19 or improved neural 
regeneration with FC-A51. While DP-005 is generally a weaker stabilizer than FC-A for 14-3-3 PPIs, here 
we revealed that, in contrast, DP-005 has the strongest stabilizing capability of all FCs for the p65/14-3-
3 interaction, being 10-fold more potent than FC-A. The structural elucidation of the DP-005 binding 
mode identified the key elements required for highly cooperative binding, including specific hydrophobic 
contacts with the p65 partner epitope and 14-3-3 K122 as a polar anchor.  
Cooperativity analysis has been shown to be a powerful tool to explain and compare the efficacy of PPI 
stabilizers and to optimize their affinity.11,12 The high cooperativity of DP-005 for stabilizing the p65/14-
3-3 interaction highlights that a relatively small modification to a small-molecule PPI stabilizer can have 
profound effects on the magnitude of the cooperativity. Specifically, the results revealed a strong increase 
in PPI selectivity by virtue of this cooperativity. The non-differentiated stabilizing effects of FC-A, FC-J 
and FC-NAc on the p65/14-3-3 complex demonstrate that a higher intrinsic affinity of the stabilizer (FC-
A and FC-J have similar binding affinities towards 14-3-3, while FC-NAc has a significantly higher af-
finity11,23) does not necessarily translate into better PPI stabilization. The higher cooperativity of DP-005 
for the p65/14-3-3 PPI resulted in its most favorable stabilization, while simultaneously featuring a similar 
or weaker capacity to stabilize other 14-3-3 PPIs, thus leading to selectivity. High potency and selectivity 
are needed in drug discovery to allow low doses of compound to be used but also to minimize off-target 
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effects. Cooperativity analysis as described here represents an excellent approach to define the concen-
tration regime under which a stabilizer might be useful and identify compounds likely to elicit good se-
lectivity early in the drug discovery process. 
In conclusion, this study provides the structural and biophysical basis of the p65/14-3-3 interaction as an 
important step in the identification and rational design of small-molecule modulators. Specifically the FC 
natural products and derivatives are shown to be highly promising tool compounds, with chemical entries 
to achieving PPI selective stabilization, by means of cooperativity. The high cooperativity of the most 
promising compound DP-005 also results in a low threshold concentration for realizing PPI-stabilization. 
This study highlights the way towards selective PPI stabilization, with cooperativity analysis providing 
an analytical tool to guide compound or stabilizer optimization in PPI drug discovery projects. 
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